

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ABSTRAL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

ACTEMRA SC

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

RHEUMATOID ARTHRITIS, GIANT CELL ARTERITIS: Prescribed by or in consultation with a rheumatologist.  
JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a dermatologist, rheumatologist, or gastroenterologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. GIANT CELL ARTERITIS: Failure of methotrexate or azathioprine, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ACTIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

16 years and older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Member is already taking and is tolerant to around-the-clock opioid therapy. Members are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ACYCLOVIR

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ADCIRCA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members on concomitant nitrates (e.g., Nitrodur, Nitrobid, Nitrostat, Isordil, Ismo). Members on concomitant guanylate cyclase stimulator, such as riociguat (Adempas).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ADEMPAS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members on concomitant phosphodiesterase (PDE) inhibitors (e.g., sildenafil, tadalafil, vardenafil, dipyridamole or theophylline) or nitrates (e.g., Nitrodur, Nitrobid, Nitrostat, Isordil, Ismo).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AFINITOR

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

BREAST CANCER: hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative recurrent or metastatic disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist. TUBEROUS SCLEROSIS COMPLEX ASSOCIATED PARTIAL ONSET SEIZURES: Prescribed by or in consultation with an oncologist or neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RENAL CELL CARCINOMA WITH CLEAR CELL HISTOLOGY: Failure of one prior therapy (e.g., Votrient, Sutent), unless contraindicated or clinically significant adverse effects are experienced. BREAST CANCER: Prescribed in combination with exemestane, fulvestrant or tamoxifen AND history of prior endocrine therapy (e.g., letrozole, anastrozole) unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AIMOVIG

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member experiences 4 or more migraine days per month for at least 3 months. CONTINUATION OF THERAPY: Member is responding positively to therapy as evidenced by a reduction in migraine days per month from baseline.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist, headache, or pain specialist.

#### **Coverage Duration:**

Initial: 3 months. Reauthorizations: 6 months.

#### **Other Criteria:**

Failure of two of the following oral migraine preventative therapies, each from different therapeutic classes, unless contraindicated or clinically significant adverse effects are experienced: antiepileptic drugs (e.g., divalproex sodium, sodium valproate, topiramate), beta-blockers (e.g., metoprolol, propranolol, timolol), antidepressants (e.g., amitriptyline, venlafaxine).



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AJOVY

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member experiences 4 or more migraine days per month for at least 3 months. CONTINUATION OF THERAPY: Member is responding positively to therapy as evidenced by a reduction in migraine days per month from baseline.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist, headache or pain specialist.

#### **Coverage Duration:**

Initial: 3 months. Reauthorizations: 6 months.

#### **Other Criteria:**

Failure of two of the following oral migraine preventative therapies, each from different therapeutic classes, unless contraindicated or clinically significant adverse effects are experienced: antiepileptic drugs (e.g., divalproex sodium, sodium valproate, topiramate), beta-blockers (e.g., metoprolol, propranolol, timolol), antidepressants (e.g., amitriptyline, venlafaxine).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ALECENSA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that the patient does or does not have anaplastic lymphoma kinase (ALK)-positive disease.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ALUNBRIG

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Disease is ALK-positive.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

AMITRIPTYLINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AMITRIPTYLINE/CHLORDIAZEPOXIDE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: duloxetine, escitalopram, or venlafaxine XR.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

AMITRIPTYLINE/PERPHENAZINE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Depression: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: duloxetine, escitalopram, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AMPHOTERICIN B

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Abelcet only: Failure of conventional amphotericin B therapy unless contraindicated or clinically significant adverse effects are experienced. Ambisome when treating patients with Aspergillus species, Candida species and/or Cryptococcus species infections: Failure of conventional amphotericin B therapy unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

AMPYRA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ANTIHISTAMINES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Allergic rhinitis: Failure to two of the following, unless contraindicated or clinically significant adverse effects are experienced: levocetirizine, desloratadine, fluticasone propionate nasal suspension, flunisolide nasal solution or triamcinolone acetonide nasal inhaler.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

ANTIHISTAMINE COMBINATIONS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Allergic rhinitis: Failure to two of the following, unless contraindicated or clinically significant adverse effects are experienced: levocetirizine, desloratadine, fluticasone propionate nasal suspension, flunisolide nasal solution or triamcinolone acetonide nasal inhaler.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ARANESP

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Anemia due to myelodysplastic syndrome. Myelofibrosis-associated anemia.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of Procrit, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ARIKAYCE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Positive sputum culture after at least 6 consecutive months of a multidrug background regimen therapy (e.g., clarithromycin or azithromycin, ethambutol, and rifamycin). CONTINUATION OF THERAPY: documentation of at least 3 consecutive negative monthly sputum cultures in the first 6 months of therapy or at least 2 consecutive negative monthly sputum cultures in the last 2 months of therapy. Member has not received Arikayce treatment for more than 12 months after converting to negative sputum status.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an infectious disease specialist or pulmonologist.

#### **Coverage Duration:**

Initial: 6 months. Reauthorizations: 12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

AUBAGIO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AUSTEDO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

TARDIVE DYSKINESIA: Development of tardive dyskinesia is secondary to a centrally acting dopamine receptor blocking agent (neuroleptic) (e.g., first- or second-generation antipsychotics such as chlorpromazine or aripiprazole, antiemetics such as promethazine or metoclopramide, the tri-cyclic antidepressant amoxapine).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

HUNTINGTON'S DISEASE: Prescribed by or in consultation with a neurologist. TARDIVE DYSKINESIA: Prescribed by or in consultation with a psychiatrist or neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

HUNTINGTON'S DISEASE: Failure of tetrabenazine, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

AVASTIN

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Glioblastoma: Patient has progressive disease.

#### **Age Restrictions:**

Age 18 or older.

#### **Prescriber Restrictions:**

All cancer indications: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Non-squamous non-small cell lung cancer: Prescribed in combination with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease. Metastatic renal cell carcinoma: Prescribed in combination with interferon alfa.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BALVERSA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of susceptible fibroblast growth factor receptor (FGFR) 3 or FGFR2 genetic alterations.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Disease has progressed during or following at least one line of platinum-containing chemotherapy.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BAXDELA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Current culture and sensitivity report shows isolated pathogen is a gram-positive or gram-negative organism susceptible to delafloxacin.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

14 days.

#### **Other Criteria:**

Failure of one fluoroquinolone, unless all are contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

BELEODAQ

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BELSOMRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For patients 65 years of age and older: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam. For patients under 65 years of age: Failure of zolpidem or zolpidem CR, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

BENLYSTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Previous anaphylaxis to Benlysta, severe active lupus nephritis or severe active central nervous system lupus.

#### **Required Medical Information:**

Documentation of systemic lupus erythematosus positive for anti-nuclear antibody (ANA) and/or anti-double-stranded DNA [anti-dsDNA].

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Currently receiving standard therapy for systemic lupus erythematosus that includes one or more of the following agents, unless all agents are contraindicated: glucocorticoids (e.g., prednisone), antimalarial (e.g., hydroxychloroquine or chloroquine), non-biologic immunosuppressants (e.g., azathioprine, methotrexate, mycophenolate).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BENZTROPINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Parkinsons disease/Parkinsonism: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amantadine, levodopa/carbidopa, entacapone, pramipexole, ropinirole, selegiline.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

BLEOMYCIN

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

BOSULIF

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that the member has Philadelphia chromosome positive disease.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BOTOX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CHRONIC MIGRAINE HEADACHE: Persistent history of chronic, debilitating migraine headaches with frequent attacks on more than 15 days per month.

#### **Age Restrictions:**

Strabismus or blepharospasm associated with dystonia: 12 years of age or older.

#### **Prescriber Restrictions:**

Chronic migraine headache: Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Chronic migraine headache: Failure of prophylactic treatment with ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: divalproex, topiramate, timolol or propranolol AND Failure of abortive therapy with ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: sumatriptan, rizatriptan, zolmitriptan, naratriptan, almotriptan, frovatriptan, Relpax, ergotamine/caffeine or dihydroergotamine.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BRAFTOVI

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Positive for BRAF V600E or V600K mutation.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

MELANOMA: Prescribed in combination with Mektovi. COLON CANCER, RECTAL CANCER: Prescribed in combination with Mektovi and either Erbitux or Vectibix.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BRIVIACT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following generic antiepileptic drugs, unless contraindicated or clinically significant adverse effects are experienced: lamotrigine, topiramate, oxcarbazepine, carbamazepine, phenytoin, valproic acid or divalproex sodium.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

BUTABARBITAL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Insomnia: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Rozerem, Silenor 6 mg/day or less, trazodone or temazepam. For use as a daytime sedative: patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

C1 ESTERASE INHIBITOR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist, allergist, hematologist or rheumatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CABOMETYX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Non-small cell lung cancer.

**Exclusion Criteria:**

**Required Medical Information:**

Non-small cell lung cancer: Documentation of an RET gene rearrangement.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CALQUENCE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Previously received at least one prior therapy (e.g., rituximab-containing regimen).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CAPRELSA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Documentation of RET gene rearrangements.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

MEDULLARY AND DIFFERENTIATED THYROID CARCINOMA: Prescribed by or in consultation with an oncologist or endocrinologist. NON-SMALL CELL LUNG CANCER: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

DIFFERENTIATED THYROID CARCINOMA: Failure of lenvatinib or sorafenib, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CARISOPRODOL/ASPIRIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CARISOPRODOL/ASPIRIN/CODEINE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CAYSTON

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CERDELGA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Extensive metabolizer (EM) or intermediate metabolizer (IM) taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor AND IMs or poor metabolizer (PM) taking a strong CYP3A inhibitor.

#### **Required Medical Information:**

An FDA-cleared genotyping test has determined that this patient is a CYP2D6 extensive metabolizer (EM), intermediate metabolizer (IM), or poor metabolizer (PM).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CEREZYME

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Type 3 Gaucher disease.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation of at least one of the following conditions resulting from Gaucher disease: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CHLORZOXAZONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CHORIONIC GONADOTROPIN

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure. Treatment of obesity.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

CINQAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 400 cells/mcL within the past 3 months.

#### **Age Restrictions:**

18 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist, pulmonologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced. AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CLADRIBINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CLOMIPRAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Autistic disorder.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one selective serotonin reuptake inhibitor (e.g., fluoxetine, fluvoxamine, sertraline), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

COMETRIQ

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Documentation of an RET gene rearrangement.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

DIFFERENTIATED THYROID CARCINOMA: Failure of Lenvima or Nexavar unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

COPIKTRA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

COTELLIC

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Patients with wild-type BRAF melanoma.

**Required Medical Information:**

Disease is positive for the BRAF V600E or V600K mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Prescribed in combination with Zelboraf.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CRINONE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Crinone 8%: Failure to Crinone 4%, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

CROFELEMER

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Patient is on anti-retroviral therapy and failure or clinically significant adverse effects to loperamide or diphenoxylate/atropine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CRYSVITA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

DNA testing results confirm the presence of mutations in the PHEX gene or documentation of elevated serum fibroblast growth factor 23 (FGF23) levels. Current (within the last 30 days) serum phosphorus level is below the reference range for age and gender. CONTINUATION OF THERAPY: Member meets all approval criteria and has had an increase in serum phosphorus level from baseline and/or maintenance within the normal range for age and gender, while on Crysvida therapy.

#### **Age Restrictions:**

At least 1 year of age.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an endocrinologist or metabolic disease specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CYCLOBENZAPRINE HCL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

CYTARABINE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For acute non-lymphocytic leukemia: use in combination with other approved anti-cancer drugs.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DAKLINZA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDS A available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 24 weeks based on cirrhosis status, genotype, prior treatment, or ribavirin eligibility.

#### **Other Criteria:**

Must be used in combination with Sovaldi. Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Mavyret, Harvoni, Epclusa, Vosevi, and Zepatier for applicable genotypes.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DAURISMO

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Age 75 years or greater, OR medical justification supports inability to use intensive induction chemotherapy.  
Prescribed in combination with low-dose cytarabine.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

DIPYRIDAMOLE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

DISOPYRAMIDE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DOPTELET

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Recent (within the past 14 days) platelet count is less than  $50 \times 10^9/L$ . Member is scheduled to undergo a medical or dental procedure within the next 30 days.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist.

#### **Coverage Duration:**

4 weeks.

#### **Other Criteria:**

For members with platelet count less than  $40 \times 10^9/L$ , failure of Mulpleta unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

DOXEPIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ELIDEL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two medium to high potency topical corticosteroids (e.g., amcinonide, fluticasone propionate, triamcinolone acetonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone butyrate, mometasone furoate, desoximetasone, fluocinonide or betamethasone dipropionate), unless contraindicated or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

EMEND 40 MG

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

Four weeks.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EMFLAZA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Diagnosis of Duchenne muscular dystrophy (DMD) confirmed by one of the following: Genetic testing (e.g., dystrophin deletion or duplication mutation found) OR if genetic studies are negative (i.e., no mutation identified), positive muscle biopsy (e.g., absence of dystrophin protein).

#### **Age Restrictions:**

5 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of prednisone, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

EMGALITY

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member experiences 4 or more migraine days per month for at least 3 months. CONTINUATION OF THERAPY: Member is responding positively to therapy as evidenced by a reduction in migraine days per month from baseline.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist, headache or pain specialist.

#### **Coverage Duration:**

Initial: 3 months. Reauthorizations: 6 months.

#### **Other Criteria:**

Failure of two of the following oral migraine preventative therapies, each from different therapeutic classes, unless contraindicated or clinically significant adverse effects are experienced: antiepileptic drugs (e.g., divalproex sodium, sodium valproate, topiramate), beta-blockers (e.g., metoprolol, propranolol, timolol), antidepressants (e.g., amitriptyline, venlafaxine).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ENBREL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Hidradenitis suppurativa.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS, PLAQUE PSORIASIS: Prescribed by or in consultation with a rheumatologist or dermatologist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist. HIDRADENITIS SUPPURATIVA: Prescribed by or in consultation with a rheumatologist, dermatologist or gastrointestinal (GI) specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PLAQUE PSORIASIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ENDARI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Age 5 or older.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of hydroxyurea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ENTRESTO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Left ventricular ejection fraction less than or equal to 35%.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ENTYVIO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a gastrointestinal (GI) specialist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Humira or Remicade, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EPCLUSA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Treatment of HCV genotype 1, 2, 3, 4, 5, or 6 with decompensated cirrhosis and sofosbuvir or NS5A-based treatment failure.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 24 weeks based on cirrhosis status, genotype, prior treatment, or ribavirin eligibility.

#### **Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EPIDIOLEX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age greater than or equal to 2 years.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

LENNOX-GASTAUT SYNDROME: will be used as adjunctive therapy with other antiepileptic drugs (e.g., topiramate, lamotrigine, felbamate, rufinamide, clobazam, or clonazepam).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EPOETIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Anemia due to myelodysplastic syndrome. Anemia associated with myelofibrosis. Anemia secondary to combination ribavirin and interferon-alfa therapy in patients infected with hepatitis C virus.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

ERGOLOID MESYLATES

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Alzheimer's dementia: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: donepezil, memantine, rivastigmine or galantamine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ERLEADA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Concurrent use of a gonadotropin-releasing hormone (GnRH) analog or past bilateral orchiectomy. Disease is not metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or urologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ESBRIET

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ESTROGENS(Fyavolv , Mimvey Lo , Minivelle , Femhrt , Vivelle-Dot , Menostar , Premphase , Premarin , Lopreeza , Alora , Amabelz , Prempro , Mimvey , Climara Pro , Combipatch , Angeliq , Elestrin , Climara , Divigel , Duavee , Activella , Estrace , Evamist , estropipate)

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Atrophic Vaginitis and Kraurosis Vulvae: Failure to one of the following, unless contraindicated or clinically significant adverse effects are experienced: Estradiol vaginal tablet, Femring or Premarin vaginal cream.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

EVZIO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Narcan (naloxone nasal spray), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

EXONDYS 51

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Duchenne muscular dystrophy with mutation amenable to exon 51 skipping confirmed by genetic testing.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Currently stable on an oral corticosteroid regimen (e.g., prednisone), unless contraindicated or member has experienced clinically significant adverse effects.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

EYLEA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an ophthalmologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

FARYDAK

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist or oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of two prior regimens, including Velcade and an immunomodulatory agent (e.g., dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

FASENRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

#### **Age Restrictions:**

12 years of age or older.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist, pulmonologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FENTORA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FERRIPROX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of deferoxamine, Exjade or Jadenu, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FIORICET WITH CODEINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and ibuprofen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FIORINAL WITH CODEINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and ibuprofen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FIRAZYR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Age 18 or greater.

**Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist, allergist, hematologist or rheumatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**



## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

FIRDAPSE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of a baseline clinical muscle strength assessment (examples may include but are not limited to the Quantitative Myasthenia Gravis (QMG) score, triple-timed up-and-go test (3TUG), Timed 25-foot Walk test (T25FW)). CONTINUATION OF THERAPY: Member is responding positively to therapy as evidenced by clinical muscle strength assessments.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FLECTOR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Cancer-related neuropathic pain.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

Acute Pain: 4 weeks. Cancer-related neuropathic pain: Through the end of the Plan contract year.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

FLUOROURACIL

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

FORTEO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

GALAFOLD

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Amenable GLA variants (mutations) associated with benign phenotypes (i.e., phenotypes known not to cause Fabry disease), including the following GLA mutation: c.937G to T, (p.(D313Y)).

#### **Required Medical Information:**

Presence of at least one amenable GLA variant (mutation) as confirmed by one of the following resources: Galafold Prescribing Information brochure (package insert - Section 12, Table 2), Amicus Fabry GLA Gene Variant Search Tool: <http://www.fabrygenevariantsearch.com/hcp>, or Amicus Medical Information at 1-877-4AMICUS or [medinfousa@amicusrx.com](mailto:medinfousa@amicusrx.com).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a clinical geneticist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GANCICLOVIR

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GATTEX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GILENYA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Baseline QTc interval greater than or equal to 500 msec.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GILOTRIF

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER (NSCLC): Histology is squamous cell carcinoma or disease is positive for a sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation [L858R, L861Q], exon 18 point mutation [G719X], exon 20 point mutation [S768I]).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GLATIRAMER

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GLYBURIDE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:  
glipizide or glipizide/metformin combination product.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

GLYBURIDE/METFORMIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:  
glipizide or glipizide/metformin combination product.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GOCOVRI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Member is receiving levodopa-based therapy. Medical justification supports inability to use immediate-release amantadine.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of immediate-release amantadine unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

GRANIX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

GRASTEK

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Severe, unstable or uncontrolled asthma. History of any severe allergic reaction to sublingual allergen immunotherapy.

#### **Required Medical Information:**

Positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive pollen [Sweet vernal, Meadow fescue, Rye, June, Kentucky blue, Orchard, Red top, Velvet, Canary, Cereal grains (e.g. wheat, rye, barley)].

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure to 2 of the following, unless contraindicated or clinically significant adverse effects are experienced: antihistamines, leukotriene modifiers or nasal steroids.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

HARVONI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Treatment of HCV genotype 1, 4, 5, or 6 with decompensated cirrhosis and sofosbuvir or NS5A-based treatment failure. Treatment of HCV genotype 4, 5, or 6 with decompensated cirrhosis. Treatment of HCV genotype 5 or 6 in liver transplant recipients.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSA available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

8 to 24 weeks based on cirrhosis status, genotype, prior treatment, or ribavirin eligibility.

#### **Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

HERCEPTIN

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that the patient has human epidermal growth factor receptor (HER2) positive cancer.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

HETLIOZ

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

HUMAN GROWTH HORMONE

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CHILDREN AND ADOLESCENTS WITH GROWTH HORMONE DEFICIENCY, SHOX DEFICIENCY IN CHILDREN: Baseline height must be greater than 2 standard deviations below the mean for gender and age. Growth rate is such that the member is unlikely to attain an adult height in the normal range - 59 inches for girls and 63 inches for boys. TURNER SYNDROME: Confirmed by karyotype. PRADER-WILLI or NOONAN SYNDROME: Baseline height must be less than the 5th percentile for gender and age OR 2 or more standard deviations below the mean measured paternal height. Growth rate is such that the member is unlikely to attain an adult height in the normal range - 59 inches for girls and 63 inches for boys.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Adult Growth Hormone Deficiency: 12 months. HIV Wasting or Cachexia, Children: 6 months.

#### **Other Criteria:**

HIV Wasting or Cachexia: Member is being treated with concomitant antiretroviral therapy.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

HUMIRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS, PLAQUE PSORIASIS: Prescribed by or in consultation with a rheumatologist or dermatologist. CROHN'S DISEASE, ULCERATIVE COLITIS: Prescribed by or in consultation with a gastrointestinal (GI) specialist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist. HIDRADENITIS SUPPURATIVA: Prescribed by or in consultation with a rheumatologist, dermatologist or GI specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PLAQUE PSORIASIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

HYDROCODONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

3 months initial for non-malignant pain then 12 months. 12 months for cancer pain.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: MS Contin, Kadian, Duragesic, Opana ER, Avinza or Oxycontin.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

HYDROXYZINE HCL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Pruritus: Failure of one of the following topical agents, unless contraindicated or clinically significant adverse effects are experienced: betamethasone, hydrocortisone, triamcinolone, fluticasone, clobetasol, fluocinonide or fluocinolone. Anxiety: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram. All other FDA approved indications: Patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

HYDROXYZINE HCL INJECTION

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

HYDROXYZINE PAMOATE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Pruritus: Failure of one of the following topical agents, unless contraindicated or clinically significant adverse effects are experienced: betamethasone, hydrocortisone, triamcinolone, fluticasone, clobetasol, fluocinonide or fluocinolone. Anxiety: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram. All other FDA approved indications: Patient is continuing on this medication without adverse effects.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ICLUSIG

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Acute Lymphoblastic Leukemia (ALL): Documentation of Philadelphia chromosome positive (Ph+) disease.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IDH1FA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of an isocitrate dehydrogenase-2 (IDH2) mutation.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For age less than 60 years, disease has relapsed or is refractory following treatment with a first line chemotherapy regimen (e.g., cytarabine, idarubicin, daunorubicin, Vyxeos, cladribine, Rydapt, Mylotarg).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ILARIS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Acute gouty arthritis.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of current weight.

#### **Age Restrictions:**

Cryopyrin-Associated Periodic Syndromes: 4 years and older. All other covered indications: 2 years and older.

#### **Prescriber Restrictions:**

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: Prescribed by or in consultation with a dermatologist, rheumatologist, or gastrointestinal (GI) specialist. ALL OTHER COVERED INDICATIONS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ILUMYA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist or dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin. Failure of one of the following unless contraindicated or clinically significant adverse effects are experienced: Cosentyx, Humira, Inflectra, Remicade, Stelara, Taltz, and Tremfya.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

IMATINIB

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

IMBRUVICA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

CHRONIC GRAFT-VERSUS-HOST DISEASE: Prescribed by or in consultation with an oncologist, hematologist, or bone marrow transplant specialist. ALL OTHER INDICATIONS: Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

MANTLE CELL LYMPHOMA: Member has received at least one prior therapy (e.g., Rituxan, vincristine, cytarabine, cisplatin, doxorubicin, Treanda). MARGINAL ZONE LYMPHOMA: Member has received at least one prior anti-CD20-based therapy.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

IMIPRAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INDOMETHACIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of naproxen and sulindac, unless contraindicated or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INFLECTRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.

Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastrointestinal (GI) specialist.

Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INGREZZA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Development of tardive dyskinesia is secondary to a centrally acting dopamine receptor blocking agent (neuroleptic) (e.g., first- or second-generation antipsychotics such as chlorpromazine or aripiprazole, antiemetics such as promethazine or metoclopramide, the tri-cyclic antidepressant amoxapine).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a psychiatrist or neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INLYTA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

FOLLICULAR CARCINOMA, HURTHLE CELL CARCINOMA, PAPILLARY CARCINOMA: Disease is iodine refractory and either unresectable or metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

INTERFERON BETA-1A

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

INTERFERON BETA-1B

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

INTERMEZZO 1.75 MG

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

INTERMEZZO 3.5 MG

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

INTUNIV

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Attention Deficit Hyperactivity Disorder: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: dexamethylphenidate, methylphenidate or mixed amphetamine salts.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

JAKAFI

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

POLYCYTHEMIA VERA: Failure of hydroxyurea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

JUBLIA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of terbinafine tablets, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

JUXTAPID

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

JYNARQUE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a nephrologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KADCYLA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Kadcyla will be used as a single-agent therapy.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KADIAN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Medical justification as to why patient cannot take an equivalent daily dose of a generically available strength of Kadian.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KALYDECO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with cystic fibrosis who are homozygous for the F508del mutation.

#### **Required Medical Information:**

Presence of one mutation in the CFTR gene that is responsive to ivacaftor as detected by an FDA-cleared cystic fibrosis mutation test.

#### **Age Restrictions:**

6 months of age or older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KERYDIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of terbinafine tablets, unless contraindicated or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KETOROLAC TROMETHAMINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Patients with active peptic ulcer disease. Advanced renal impairment or at risk for renal failure due to volume depletion. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis and those at high risk for bleeding. Patient currently receiving aspirin or NSAIDs (Non-steroidal anti-inflammatory drugs). Patient currently receiving Probenecid or pentoxifylline.

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

5 days.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KEVEYIS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

KEVZARA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

KEYTRUDA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CLASSICAL HODGKIN LYMPHOMA, PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA:  
Prescribed by or in consultation with an oncologist or hematologist. ALL OTHER INDICATIONS: Prescribed by  
or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

KISQALI(Kisqali , Kisqali Femara Co-Pack )

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Breast cancer is hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, and advanced or metastatic.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For Kisqali: Prescribed in combination with an aromatase inhibitor (e.g., letrozole, anastrozole, or exemestane), fulvestrant, or tamoxifen. If prescribed in combination with tamoxifen: Medical justification supports need to use tamoxifen over an aromatase inhibitor or fulvestrant. For men receiving an aromatase inhibitor: Prescribed in combination with an agent that suppresses testicular steroidogenesis (e.g., gonadotropin-releasing hormone agonists).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KORLYM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Pregnancy.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KUVAN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

CONTINUATION OF THERAPY: Documentation of a reduction in blood phenylalanine levels since initiation of therapy.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

Initial: 3 months. Reauthorization: 12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

KYNAMRO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Repatha 420 mg, unless contraindicated or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

LATUDA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of two of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LAZANDA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Age 18 or greater

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Through the end of the Plan contract year.

#### **Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

LEMTRADA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of TWO of the following, unless contraindicated or clinically significant adverse effects are experienced:  
Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

LENVIMA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

RENAL CELL CARCINOMA: Prescribed in combination with Afinitor AND if histology is clear cell or unknown, failure of a regimen consisting of or including one of the following drugs unless contraindicated or clinically significant adverse effects are experienced: Avastin, Cabometyx, Inlyta, Nexavar, Opdivo, Proleukin, Sutent, Tarceva, Torisel, Votrient, or Yervoy. MEDULLARY THYROID CARCINOMA: Failure of Cometriq or Caprelsa unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LEUKINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Use Following Induction Chemotherapy in Acute Myelogenous Leukemia, Use in Mobilization and Following Transplantation of Autologous Peripheral Blood Progenitor Cells, Use in Myeloid Reconstitution After Autologous or Allogeneic Bone Marrow Transplantation, Acute Radiation Syndrome: Failure of Neupogen, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

LIDODERM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Diabetic peripheral neuropathy. Cancer-related neuropathic pain.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

LONSURF

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

COLORECTAL CANCER: Documentation that the member does or does not have the RAS (KRAS or NRAS) wild type gene. GASTRIC CANCER, GASTROESOPHAGEAL ADENOCARCINOMA: Documentation that the member does or does not have a HER2/neu-positive tumor.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

COLORECTAL CANCER: If tumor expresses the RAS wild type gene, failure of Erbitux or Vectibix, unless contraindicated or clinically significant adverse effects are experienced. GASTRIC CANCER, GASTROESOPHAGEAL ADENOCARCINOMA: If tumor is HER2/neu-positive (i.e., HER2-overexpressing), failure of Herceptin, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LORBRENA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Disease is ALK or ROS1 positive.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For ALK-positive disease: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Alecensa, Alunbrig, Zykadia. For ROS1-positive disease: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Xalkori, Zykadia.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

LOTROXEX

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Male patients.

**Required Medical Information:**

Female patient with irritable bowel symptoms persisting for at least 6 months.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LUCEMYRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Diagnosis of opioid dependence (may be limited to physiologic dependence/tolerance) or opioid use disorder. Member is currently or will be undergoing abrupt opioid discontinuation within the next seven days and one of the following: member has taken one or more opioids for at least the last three weeks OR an opioid antagonist (e.g., naltrexone) has been or will be administered after a period of opioid use. Medical justification supports why an opioid taper (e.g., with buprenorphine, methadone or other opioid) cannot be used. Lucemyra has not been prescribed for a prior opioid withdrawal event within the last 30 days or medical justification supports retreatment.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a physician specializing in one of the following areas: emergency medicine/inpatient care, pain management, addiction psychiatry.

#### **Coverage Duration:**

14 days per course of treatment.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

LUNESTA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced:  
Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

LYNPARZA CAPSULE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Mutations in the BRCA genes as detected by an FDA approved test.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

LYNPARZA TABLET

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Ovarian, fallopian tube or primary peritoneal cancer: Mutations in the BRCA genes OR member has a complete or partial response to two or more platinum-based chemotherapy regimens. Breast Cancer: Mutations in the BRCA genes and documentation of human epidermal growth factor receptor 2 (HER2)-negative disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MAVYRET

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Treatment-experienced patients with both NS3/4A protease inhibitor and NS5A inhibitor.

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDS available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

8 to 16 weeks based on genotype, cirrhosis status, prior treatment regimen.

#### **Other Criteria:**

If member has been previously treated with an HCV regimen containing NS5A inhibitor or an NS3/4A protease inhibitor, but not both, member has genotype 1.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

MEGACE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEGACE ES

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

BREAST CANCER AND ENDOMETRIAL CANCER: Megestrol acetate is being used for palliative treatment.

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ANOREXIA AND CACHEXIA ASSOCIATED WITH AIDS: Failure of dronabinol and oxandrolone, unless contraindicated or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEKINIST

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Uveal melanoma.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

MELANOMA: Positive for BRAF V600E or V600K mutation. NON-SMALL CELL LUNG CANCER, ANAPLASTIC THYROID CANCER: Positive for BRAF V600E mutation.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

NON-SMALL CELL LUNG CANCER, ANAPLASTIC THYROID CANCER: Prescribed in combination with Tafenlar.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

MEKTOVI

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Positive for BRAF V600E or V600K mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Prescribed in combination with Braftovi.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MEPERIDINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Pain: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: codeine, hydromorphone, morphine, oxymorphone, hydrocodone/acetaminophen or oxycodone.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

MEPROBAMATE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: venlafaxine, buspirone, duloxetine or escitalopram.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

METAXALONE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

METHAMPHETAMINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Treatment of obesity.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

METHOCARBAMOL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

METHOTREXATE INJ

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of generic methotrexate injection, unless contraindicated or clinically significant adverse effects are experienced.



## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

METHYLDOPA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amlodipine/benazepril, benazepril, benazepril/hydrochlorothiazide, captopril, captopril/hydrochlorothiazide, fosinopril, fosinopril/hydrochlorothiazide, lisinopril, lisinopril/hydrochlorothiazide, quinapril, quinapril/hydrochlorothiazide, losartan, losartan/hydrochlorothiazide, valsartan, valsartan/hydrochlorothiazide, irbesartan, irbesartan/hydrochlorothiazide, candesartan, candesartan/hydrochlorothiazide, carvedilol, labetalol, acebutolol, atenolol, bisoprolol, bisoprolol/hydrochlorothiazide, timolol, nadolol, propranolol, metoprolol, metoprolol/hydrochlorothiazide, pindolol, nifedipine SR, amlodipine, nicardipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

MIRVASO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Erythema of rosacea with papules or pustules: Failure of topical metronidazole, oral doxycycline or Finacea, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

MOZOBIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Must be administered in combination with a granulocyte-colony stimulating factor (G-CSF) (i.e., Neupogen, Zarxio, Granix, or Nivestym).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

MULPLETA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Recent (within the past 14 days) platelet count is less than  $50 \times 10^9/L$ . Member is scheduled to undergo a medical or dental procedure within the next 30 days.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist.

#### **Coverage Duration:**

4 weeks.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NAMENDA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Vascular dementia.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 59 years and younger. Prior authorization is not required for patients 60 years and older.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NATPARA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NERLYNX

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with capecitabine for recurrent brain metastases OR Documentation of previous treatment with trastuzumab as adjuvant therapy and disease is hormone receptor positive or early stage (stage 1-3).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NEULASTA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Mobilization of peripheral-blood progenitor cells prior to autologous transplantation. Supportive care post autologous hematopoietic cell transplantation.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NEUPOGEN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NINLARO

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Prescribed in combination with dexamethasone.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

NITROFURANTOIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Urinary tract infectious disease, Acute treatment: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: sulfamethoxazole/trimethoprim or ciprofloxacin. Urinary tract infectious disease, Prophylaxis: Patient is continuing on this medication without adverse effects.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

NIVESTYM

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS. Hematopoietic syndrome of acute radiation syndrome.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NORTHERA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

NUCALA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Blood eosinophil count of greater than or equal to 150 cells/mcL within the past 3 months.

#### **Age Restrictions:**

ASTHMA: 12 years of age or older.

#### **Prescriber Restrictions:**

ASTHMA: Prescribed by or in consultation with an allergist, pulmonologist, or immunologist. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Prescribed by or in consultation with a pulmonologist, immunologist, rheumatologist, or nephrologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ASTHMA: Prescribed in combination with ONE inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced AND Prescribed in combination with ONE long-acting beta-agonist (e.g., salmeterol, formoterol, vilanterol), unless contraindicated or clinically significant adverse effects are experienced. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: Failure of ONE glucocorticoid, unless contraindicated or clinically significant adverse events are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUEDEXTA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUPLAZID

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

NUVIGIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

NUZYRA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Request is for continuation of therapy initiated in an acute care hospital from which member was discharged OR Culture and sensitivity (C&S) report for the current infection shows isolated pathogen is an organism susceptible to omadacycline, unless provider submits documentation that obtaining a C&S report is not feasible.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

14 days.

#### **Other Criteria:**

For members initiating Nuzyra therapy outside of an acute care hospital, one of the following (a, b, or c): a) If a C&S report is available: Failure of 2 antibiotics to which the isolated pathogen is susceptible (if available) per C&S report, unless all are contraindicated or clinically significant adverse effects are experienced. b) C&S report shows resistance or lack of susceptibility of the isolated pathogen to all antibiotics FDA-approved for member's diagnosis. c) If provider documents that obtaining a C&S report is not feasible: Failure of 2 antibiotics indicated for member's diagnosis (if available), unless all are contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OCALIVA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Must be used in combination with ursodeoxycholic acid unless patient is intolerant to ursodeoxycholic acid.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

OCREVUS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Relapsing Forms Of Multiple Sclerosis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ODOMZO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OFEV

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

OLUMIANT

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one of the following agents, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine, or auranofin. Failure of at least one TNF inhibitor unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OPSUMIT

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ORALAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Severe, unstable or uncontrolled asthma. History of any severe allergic reaction to sublingual allergen immunotherapy.

#### **Required Medical Information:**

Positive skin test or in vitro testing for pollen-specific IgE antibodies for Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an allergist or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure to 2 of the following, unless contraindicated or clinically significant adverse effects are experienced: antihistamines, leukotriene modifiers or nasal steroids.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ORENITRAM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

ORLISSA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

For 200 mg twice daily requests, members with osteoporosis.

#### **Required Medical Information:**

Continuation of therapy: improvement in dysmenorrhea, dyspareunia, pelvic pain/induration/tenderness, or size of endometrial lesions. Total duration of therapy has not exceeded 6 months for 200 mg twice daily or 24 months for 150 mg once daily dosing.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gynecologist.

#### **Coverage Duration:**

Up to 6 months for 200 mg twice daily or up to 12 months for 150 mg once daily.

#### **Other Criteria:**

Failure of ONE non-steroidal anti-inflammatory drug (e.g., ibuprofen, naproxen, fenoprofen, ketoprofen, mefenamic acid, meclofenamate, indomethacin, tolmetin, diclofenac, etodolac, diflunisal, meloxicam, piroxicam) or ONE progestin-containing agent (e.g., norethindrone, ethinyl estradiol with (desogestrel, ethynodiol diacetate, drospirenone, etonogestrel, levonorgestrel, norelgestromin, norethindrone, norgestimate, or norgestrel), estradiol valerate/dienogest, mestranol/norethindrone, depot injectable medroxyprogesterone acetate), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ORKAMBI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Presence of homozygous F508del mutation in an FDA-cleared cystic fibrosis mutation test.

**Age Restrictions:**

2 years of age or older.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ORPHENADRINE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OSMOLEX ER

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Medical justification supports inability to use immediate-release amantadine.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of immediate-release amantadine unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

OXERVATE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an ophthalmologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PALYNZIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Recent (within 90 days) phenylalanine (Phe) blood level is greater than 600 micromol/L. CONTINUATION OF THERAPY: Positive response as evidenced by one of the following: a) Blood Phe level has decreased by at least 20% from pre-treatment baseline, b) Blood Phe level is less than or equal to 600 micromol/L, c) Member has been using 20 mg per day for at least 6 months, but a dose titration to 40 mg per day is being requested after failure to meet therapeutic targets (a or b above).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an endocrinologist, metabolic disease specialist, or genetic disease specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PENTAZOCINE/NALOXONE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: codeine, hydromorphone, morphine, oxymorphone, hydrocodone/acetaminophen or oxycodone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PERSERIS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of TWO of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: aripiprazole, ziprasidone, quetiapine, olanzapine, risperidone, asenapine, iloperidone, paliperidone.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

PHENOBARBITAL

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Partial seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, tiagabine, levetiracetam, gabapentin, lamotrigine, oxcarbazepine, primidone or divalproex. Generalized seizures: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: carbamazepine, phenytoin, topiramate, levetiracetam, primidone or lamotrigine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PRALUENT

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Heterozygous Familial Hypercholesterolemia : Documentation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of heterozygous familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Documentation of an LDL of 70 mg/dL or greater AND documented history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Documentation of LDL reduction while on Praluent therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PREVYMIS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Member is receiving pimozide or ergot alkaloids. Member is receiving cyclosporine co-administered with pitavastatin or simvastatin.

#### **Required Medical Information:**

Intravenous (IV) Prevymis: Medical justification why the member cannot use oral therapy.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncology, hematology, infectious disease, or transplant specialist.

#### **Coverage Duration:**

Through day 100 post-transplantation.

#### **Other Criteria:**

Failure of generic valacyclovir or generic ganciclovir, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROCARDIA CAPSULES

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

CHRONIC STABLE ANGINA: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: nifedipine SR, amlodipine or nicardipine. VASOSPASTIC ANGINA: Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: nifedipine SR or amlodipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

PROLASTIN C

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a pulmonologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

PROLIA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Hypocalcemia (unless corrected prior to initiating therapy).

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

For men with non-metastatic prostate cancer: Receiving or has received androgen deprivation therapy [i.e., leuprolide (Lupron), bicalutamide (Casodex) or Nilandron]. For women with breast cancer: Receiving or has received adjuvant aromatase inhibitor therapy [i.e., anastrozole (Arimidex), exemestane (Aromasin) or letrozole (Femara)].



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROMACTA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Thrombocytopenia in Chronic Hepatitis C: Documentation of current or planned interferon-based treatment of chronic hepatitis C.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Chronic Immune (Idiopathic) Thrombocytopenia: Failure of a corticosteroid (e.g., prednisone, methylprednisolone, or dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

PROTOPIC

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Tacrolimus 0.1%: 16 years and older.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two medium to high potency topical corticosteroids (e.g., amcinonide, fluticasone propionate, triamcinolone acetonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone butyrate, mometasone furoate, desoximetasone, fluocinonide or betamethasone dipropionate), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

PROVIGIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Multiple sclerosis-related fatigue.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

PURIXAN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Lymphoblastic lymphoma.

**Exclusion Criteria:**

**Required Medical Information:**

Member has a documented swallowing disorder or an inability to swallow tablets or capsules.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of mercaptopurine tablets, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

QUALAQUIN

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Babesiosis. Plasmodium vivax malaria.

#### **Exclusion Criteria:**

For the treatment or prevention of nocturnal leg cramps.

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Malaria: 7 days. Babesiosis: 7-10 days.

#### **Other Criteria:**

Plasmodium vivax malaria: Infection is chloroquine-resistant.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RADICAVA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Forced vital capacity greater than or equal to 80%, disease duration of less than or equal to 2 years, functionally retains most activities of daily living (defined as a baseline revised ALS Functional Rating Scale (ALSFRS-R) score with greater than or equal to 2 points in each of the 12 items, meets diagnostic criteria of definite or probable amyotrophic lateral sclerosis (ALS) based on El Escorial revised criteria. CONTINUATION OF THERAPY: Member continues to retain most activities of daily living, forced vital capacity greater than or equal to 80%, and ALSFRS-R score with greater than or equal to 2 points in each of the 12 items.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Prescribed in combination with riluzole unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RAYALDEE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Patient has stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D level less than 30 ng/mL.

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RELISTOR

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of Amitiza and Movantik, unless contraindicated or clinically significant adverse effects are experienced.



## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

REMICADE

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Wegener's Granulomatosis.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Psoriatic Arthritis/Plaque Psoriasis: Prescribed by or in consultation with a rheumatologist or dermatologist.

Crohn's Disease/Ulcerative Colitis: Prescribed by or in consultation with a gastrointestinal (GI) specialist.

Rheumatoid Arthritis/Ankylosing Spondylitis: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

Plaque Psoriasis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

REPATHA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Heterozygous or Homozygous Familial Hypercholesterolemia : Documentation (e.g., medical records, chart notes, laboratory values) of LDL level suggestive of a diagnosis of familial hypercholesterolemia (e.g., Adults: LDL greater than 190 mg/dL). Hypercholesterolemia: Documentation of an LDL of 70 mg/dL or greater AND documented history of clinical atherosclerotic cardiovascular disease defined as one of the following: Acute coronary syndromes, Myocardial Infarction, Stable or unstable angina, Coronary or other arterial revascularization (e.g., percutaneous coronary intervention or coronary artery bypass graft surgery), Stroke, Peripheral artery disease presumed to be of atherosclerotic origin, Transient ischemic attack (TIA), Clinically significant coronary heart disease (CHD) diagnosed by invasive or noninvasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography, or nuclear imaging), Carotid artery occlusion greater than 50% without symptoms, Renal artery stenosis or renal artery stent procedure. CONTINUATION OF THERAPY: Documentation of LDL reduction while on Repatha therapy AND, if tolerated, confirmation of continued statin therapy at the maximally tolerated dose.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a cardiologist, endocrinologist, or lipid specialist.

#### **Coverage Duration:**

6 months.

#### **Other Criteria:**

Failure of two of the following at maximally tolerated doses, unless contraindicated or clinically significant adverse effects are experienced: atorvastatin, rosuvastatin, simvastatin, ezetimibe/simvastatin, pitavastatin, pravastatin, fluvastatin, or lovastatin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

RESTASIS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of one ophthalmic corticosteroid unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

REVATIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members on concomitant nitrates (e.g., Nitrodur, Nitrobid, Nitrostat, Isordil, Ismo). Members on concomitant guanylate cyclase stimulator, such as riociguat (Adempas).

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

REVC0VI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

REVLIMID

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Members who are pregnant.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

REXULTI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of aripiprazole and one of the following generic atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine, ziprasidone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

RITUXIMAB

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

All oncology indications: Prescribed by or in consultation with an oncologist or hematologist. Rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis: Prescribed by or in consultation with a rheumatologist. Pemphigus vulgaris: Prescribed by or in consultation with a dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Rheumatoid Arthritis: Prescribed in combination with methotrexate, unless contraindicated or clinically significant adverse effects were experienced with prior methotrexate therapy AND failure of Enbrel or Humira, unless contraindicated or clinically significant adverse effects are experienced. Granulomatosis with polyangiitis, Microscopic polyangiitis: Prescribed in combination with a glucocorticoid (e.g. prednisone, prednisolone, dexamethasone).



## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

RUBRACA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

NON-MAINTENANCE TREATMENT: Mutations in the BRCA genes as detected by an FDA approved test.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

MAINTENANCE TREATMENT: Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

RYDAPT

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Acute Myeloid Leukemia: Positive for the FLT3 mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Acute Myeloid Leukemia: Prescribed by or in consultation with an oncologist or hematologist. Advanced Systemic Mastocytosis: Prescribed by or in consultation with an oncologist, allergist, or immunologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Acute Myeloid Leukemia: for induction therapy, prescribed in combination with cytarabine and daunorubicin OR for consolidation therapy, prescribed in combination with cytarabine.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

SAVELLA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Depression.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Fibromyalgia: Failure of duloxetine or Lyrica, unless contraindicated or clinically significant adverse effects are experienced. Depression: Failure of ONE of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SEROQUEL XR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Schizophrenia: Failure of two of the following generic atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: risperidone, olanzapine, quetiapine immediate release, ziprasidone, aripiprazole.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SILIQ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist or dermatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced:  
methotrexate, cyclosporine or acitretin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SIMPONI(auto-injector, prefilled syringe)

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist. ULCERATIVE COLITIS: Prescribed by or in consultation with a gastroenterologist. RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SIMPONI ARIA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist.  
RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS: Prescribed by or in consultation with a rheumatologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SOMA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SOMAVERT

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Inadequate response to surgery or radiation therapy, unless surgery or radiation therapy is not appropriate for the patient.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SONATA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced:  
Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

SOVALDI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. For the treatment of hepatitis C virus genotypes 5 and 6. Treatment of HCV genotype 2 or 3 in liver transplant recipients.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

Criteria will be applied consistent with current AASLD-IDSAs guidance.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: Mavyret, Harvoni, Epclusa, Vosevi, and Zepatier for applicable genotypes.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

SPRAVATO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Currently on an oral antidepressant (must not be an agent previously tried and failed). CONTINUATION OF THERAPY: Member is responding positively to therapy and is using Spravato in combination with an oral antidepressant.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

Initial: 4 weeks. Reauthorization: 6 months.

#### **Other Criteria:**

Failure of two antidepressants (e.g., selective serotonin reuptake inhibitor [SSRI], serotonin-norepinephrine reuptake inhibitor [SNRI], tricyclic antidepressant [TCA], bupropion, mirtazapine) from two different classes, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SPRITAM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Medical justification must be provided why patient cannot take generic levetiracetam tablets or liquid.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

SPRYCEL

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Documentation that the member has Philadelphia chromosome positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. ALL OTHER COVERED ONCOLOGY INDICATIONS: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

STIVARGA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

STRENSIQ

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

SUBSYS

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Age 18 or greater.

**Prescriber Restrictions:**

**Coverage Duration:**

Through the end of the Plan contract year.

**Other Criteria:**

Patient is already taking and is tolerant to around-the-clock opioid therapy. Patients are considered opioid tolerant when taking another opioid daily for a week or longer (for example, at least 60 mg of oral morphine per day or an equianalgesic dose of another opioid).

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

SURMONTIL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Irritable bowel syndrome.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Depression: Failure of one of the following generic antidepressants, unless contraindicated or clinically significant adverse effects are experienced: bupropion, bupropion SR, bupropion XL, citalopram, desvenlafaxine succinate, duloxetine, escitalopram, fluoxetine, mirtazapine, sertraline, venlafaxine, or venlafaxine XR.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SYMDEKO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Presence of homozygous F508del mutation or at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor.

**Age Restrictions:**

Age greater than or equal to 12 years.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SYMLINPEN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Previous use of mealtime insulin therapy or an insulin pump.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

SYMPAZAN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Medical justification supports inability to use clobazam tablets and oral suspension (e.g., contraindications to excipients).

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

TAGRISSO

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Disease is positive for either of the following (a or b): a) sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation (L858R, L861Q), exon 18 point mutation (G719X), exon 20 point mutation (S768I)), OR b) T790M mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

TAKHZYRO

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Age greater than or equal to 12 years.

**Prescriber Restrictions:**

Prescribed by or in consultation with an immunologist, allergist, hematologist, or rheumatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TALZENNA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of human epidermal growth factor receptor 2 (HER2)-negative disease and mutation in the BRCA genes as detected by an FDA-approved test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**



## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

TARCEVA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Disease is positive for a sensitizing EGFR mutation (e.g., exon 19 deletion or insertion, exon 21 point mutation (L858R, L861Q), exon 18 point mutation (G719X), exon 20 point mutation (S768I)).

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

PANCREATIC CANCER: Prescribed in combination with gemcitabine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TASIGNA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

Members with hypokalemia, hypomagnesemia, or long QT syndrome.

#### **Required Medical Information:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Documentation that the member has Philadelphia chromosome positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

CHRONIC MYELOGENOUS LEUKEMIA, ACUTE LYMPHOBLASTIC LEUKEMIA: Prescribed by or in consultation with an oncologist or hematologist. GASTROINTESTINAL STROMAL TUMOR: Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

GASTROINTESTINAL STROMAL TUMOR: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: imatinib, Sutent or Stivarga.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

TAVALISSE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of a corticosteroid (e.g., prednisone, methylprednisolone, or dexamethasone), unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

TECENTRIQ

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

EXTENSIVE-STAGE SMALL CELL LUNG CANCER: Prescribed in combination with carboplatin and etoposide. TRIPLE NEGATIVE BREAST CANCER: Hormone-receptor (HR)-negative, estrogen-receptor (ER)-negative, and human epidermal growth factor receptor 2 (HER2)-negative disease. Prescribed in combination with protein-bound paclitaxel (nab-paclitaxel). Tumor expresses PD-L1.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

NON-SMALL CELL LUNG CANCER: If a known epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberration exists, then for ALK+ disease: prior trial of Xalkori, Alecensa, or Zykadia OR for EGFR+ disease: prior trial of Tarceva, Gilotrif or Iressa.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

TECFIDERA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TEGSEDI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documented transthyretin (TTR) mutation. Documented amyloid deposition on biopsy or medical justification is provided as to why treatment should be initiated in the presence of a negative biopsy or no biopsy. Member has not had a liver transplant. CONTINUATION OF THERAPY: Maintained on therapy with positive response, including but not limited to improvement in any of the following parameters: 1) neuropathy (motor function, sensation, reflexes, walking ability), 2) nutrition (body mass index), 3) cardiac parameters (Holter monitoring, echocardiography, electrocardiogram, plasma BNP or NT-proBNP, serum troponin), 4) renal parameters (creatinine clearance, urine albumin), 5) ophthalmic parameters (eye exam).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a neurologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

TENEX

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amlodipine/benazepril, benazepril, benazepril/hydrochlorothiazide, captopril, captopril/hydrochlorothiazide, fosinopril, fosinopril/hydrochlorothiazide, lisinopril, lisinopril/hydrochlorothiazide, quinapril, quinapril/hydrochlorothiazide, losartan, losartan/hydrochlorothiazide, valsartan, valsartan/hydrochlorothiazide, irbesartan, irbesartan/hydrochlorothiazide, candesartan, candesartan/hydrochlorothiazide, carvedilol, labetalol, acebutolol, atenolol, bisoprolol, bisoprolol/hydrochlorothiazide, timolol, nadolol, propranolol, metoprolol, metoprolol/hydrochlorothiazide, pindolol, nifedipine SR, amlodipine, nicardipine.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

TETRABENAZINE

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TIBSOVO

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Presence of an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test (e.g., Abbott RealTime IDH1 Assay).

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

For age less than 60 years, disease has relapsed or is refractory following treatment with a first-line chemotherapy regimen (e.g., cytarabine, idarubicin, daunorubicin, cladribine, midostaurin).

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

TREMFYA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a rheumatologist or dermatologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of ONE of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, cyclosporine, or acitretin.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

TRIHEXYPHENIDYL

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Parkinsons disease/Parkinsonism: Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced: amantadine, levodopa/carbidopa, entacapone, pramipexole, ropinirole, selegiline.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

TYMLOS

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Total duration of therapy on parathyroid hormone (PTH) analogs (e.g., Tymlos, Forteo) has not exceeded 2 years.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of a bisphosphonate (e.g., alendronate) unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

TYSABRI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

MULTIPLE SCLEROSIS: Prescribed by or in consultation with a neurologist. CROHN'S DISEASE: Prescribed by or in consultation with a GI specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RELAPSING FORMS OF MULTIPLE SCLEROSIS: Failure or clinically significant adverse effects to one of the following: Aubagio, Tecfidera, Gilenya, Avonex, Betaseron, Plegridy, glatiramer, Copaxone, Glatopa, Extavia or Rebif. CROHN'S DISEASE: Failure or clinically significant adverse effects to Humira or Remicade.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ULTRAVATE LOTION

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of generic halobetasol propionate and generic clobetasol propionate, unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

UPTRAVI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VALCHLOR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following skin-directed therapies unless contraindicated or clinically significant adverse effects are experienced: topical corticosteroid (e.g., betamethasone, clobetasol), topical retinoid (e.g., Targretin, Avage, Fabior, Tazorac), topical imiquimod (Aldara).



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VANCOGIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

C. Diff diarrhea: 14 days. Staph enterocolitis: 10 days. Recurrent C. Diff: 12 weeks.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

VENCLEXTA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

AML: Age 60 years or greater, OR medical justification supports inability to use intensive induction chemotherapy. Prescribed in combination with azacitidine, decitabine, or low-dose cytarabine.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

CLL/SLL, MANTLE CELL LYMPHOMA: Failure of at least one previous therapy (e.g., for CLL/SLL Imbruvica, Campath, or high-dose methylprednisolone with Rituxan, for mantle cell lymphoma a Rituxan based regimen), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VERSACLOZ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Psychotic disorder associated with Parkinson's disease.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of clozapine (Clozaril) or FazaClo, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

VERZENIO

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

For men receiving an aromatase inhibitor: Prescribed in combination with an agent that suppresses testicular steroidogenesis (e.g., gonadotropin-releasing hormone agonists).

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VIBERZI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of loperamide unless contraindicated or clinically significant adverse effects are experienced AND For members 64 years and younger, failure of diphenoxylate-atropine (Lomotil) or dicyclomine, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

VIMOVO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: pantoprazole, lansoprazole or omeprazole AND For osteoarthritis or rheumatoid arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: ibuprofen, diclofenac sodium or potassium, etodolac, fenoprofen, ketoprofen, meloxicam, naproxen, oxaprozin, piroxicam, salsalate, sulindac, tolmetin OR For ankylosing spondylitis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: diclofenac sodium, naproxen or sulindac OR For juvenile idiopathic arthritis: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: etodolac, ibuprofen, meloxicam, naproxen, oxaprozin, tolmetin.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VINBLASTINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation that vinblastine is being used as palliative therapy.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VINCRISTINE

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Patients with the demyelinating form of Charcot-Marie-Tooth syndrome.

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**



## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

VITRAKVI

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

Known acquired tropomyosin receptor kinase resistance mutation.

**Required Medical Information:**

Documentation of positive neurotrophic receptor tyrosine kinase gene fusion mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Disease has progressed following standard first-line treatment unless contraindicated, clinically significant adverse effects are experienced, or there are not such alternative treatments available.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VIZIMPRO

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation of EGFR exon 19 deletion or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

VOSEVI

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 weeks.

#### **Other Criteria:**

If HCV genotype 1, 2, 3, 4, 5 or 6, member has previously been treated with an HCV regimen containing one of the following NS5A inhibitors: daclatasvir, elbasvir, ledipasvir, ombitasvir, or velpatasvir. Alternatively, if HCV genotype is 1a or 3, member has previously been treated with an HCV regimen containing sofosbuvir.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

VOTRIENT

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

VRAYLAR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure of TWO of the following atypical antipsychotics, unless contraindicated or clinically significant adverse effects are experienced: aripiprazole, ziprasidone, quetiapine, olanzapine, risperidone.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XALKORI

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL CELL LUNG CANCER: Documentation of ALK, ROS1, or MET positive disease.  
INFLAMMATORY MYOFIBROBLASTIC TUMOR, ANAPLASTIC LARGE CELL LYMPHOMA:  
Documentation of ALK-positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XATMEP

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

Less than 18 years of age.

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist (for acute lymphoblastic leukemia) or rheumatologist (for polyarticular juvenile idiopathic arthritis).

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Medical justification as to why member cannot use methotrexate tablets.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XELJANZ

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

RHEUMATOID ARTHRITIS: Prescribed by or in consultation with a rheumatologist. PSORIATIC ARTHRITIS: Prescribed by or in consultation with a rheumatologist or dermatologist. ULCERATIVE COLITIS (IMMEDIATE-RELEASE ONLY): Prescribed by or in consultation with a gastrointestinal (GI) specialist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

RHEUMATOID ARTHRITIS: Failure of one of the following, unless contraindicated or clinically significant adverse effects are experienced: methotrexate, sulfasalazine, hydroxychloroquine, d-penicillamine, azathioprine or auranofin. PSORIATIC ARTHRITIS: Failure of methotrexate, unless predominantly axial disease, contraindicated, or clinically significant adverse effects are experienced.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

XEOMIN

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

XERMELO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Prescribed in combination with a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Failure to a trial of a somatostatin analog (e.g., octreotide, lanreotide) unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

XOLAIR

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

ASTHMA: Positive skin test or in vitro reactivity to a perennial aeroallergen AND immunoglobulin E (IgE) level greater than or equal to 30 IU/mL.

#### **Age Restrictions:**

ASTHMA: 6 years of age or older. CHRONIC IDIOPATHIC URTICARIA: 12 years of age or older.

#### **Prescriber Restrictions:**

ASTHMA: Prescribed by or in consultation with a pulmonologist, immunologist, or allergist. CHRONIC IDIOPATHIC URTICARIA: Prescribed by or in consultation with an allergist, dermatologist, or immunologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

ASTHMA: Failure of one inhaled corticosteroid (e.g., beclomethasone, budesonide, flunisolide, fluticasone, mometasone, ciclesonide), unless contraindicated or clinically significant adverse effects are experienced. CHRONIC IDIOPATHIC URTICARIA: Failure of one H1 Antihistamine (e.g., levocetirizine or desloratadine), unless contraindicated or clinically significant adverse effects are experienced.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

XOSPATA

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

Documentation of the presence of a FLT3 mutation.

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

XTANDI

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or urologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

YERVOY

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Small cell lung cancer.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

SMALL CELL LUNG CANCER: Failure of a platinum-containing regimen (e.g., cisplatin, carboplatin containing regimen). SMALL CELL LUNG CANCER, RENAL CELL CARCINOMA: Prescribed in combination with Opdivo.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

YONSA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or urologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

Prescribed in combination with methylprednisolone. Member has previously had bilateral orchiectomy, failed androgen deprivation therapy (ADT) or will use ADT concurrently with Yonsa.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

ZALTRAP

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Prescribed in combination with irinotecan or FOLFIRI (5-fluorouracil, leucovorin, and irinotecan). Previous treatment with one of the following: oxaliplatin-containing regimen (e.g., FOLFIRI, FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin], CapeOX [capecitabine, oxaliplatin]) OR 5-fluorouracil and leucovorin containing regimen OR capecitabine containing regimen.



## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZARXIO

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D. Myelodysplastic syndrome. Neutropenia in patients with HIV/AIDS. Hematopoietic syndrome of acute radiation syndrome.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ZEJULA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Completed two or more platinum-based chemotherapy regimens and is in a complete or partial response.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

ZELBORAF

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

MELANOMA, ERDHEIM-CHESTER DISEASE: Positive for the BRAF V600 mutation. NON-SMALL CELL LUNG CANCER, COLORECTAL CANCER: Positive for the BRAF V600E mutation. DIFFERENTIATED THYROID CARCINOMA: Positive for the BRAF mutation.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or hematologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**

NON-SMALL CELL LUNG CANCER: Failure of Tafenlar or Mekinist, unless contraindicated or clinically significant adverse effects are experienced.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

#### **Prior Authorization Group Description:**

ZEPATIER

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

If cirrhosis is present, confirmation of Child-Pugh A status. For genotype 1a, documentation of presence or absence of NS5A resistance-associated polymorphisms. Refer to the document, "Recommendations for Testing, Managing, and Treating Hepatitis C," by AASLD-IDSAs available at <http://www.hcvguidelines.org> for drug regimen and duration of treatment based on genotype, treatment status, previous drug regimens used, past medical history and comorbidities.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with a gastroenterologist, hepatologist or infectious disease physician.

#### **Coverage Duration:**

12 to 16 wks based on genotype,presence of NS5A resistance-associated polymorphisms,prior treatment.

#### **Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZINPLAVA

#### **Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

Documentation of positive Clostridium difficile test.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

#### **Coverage Duration:**

4 weeks.

#### **Other Criteria:**

Will receive or is currently receiving antibacterial drug treatment for Clostridium difficile infection (e.g., metronidazole, vancomycin, fidaxomicin) concomitantly with Zinplava. Has received appropriate treatment for past CDI recurrences, including a pulsed vancomycin regimen.

## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

ZOLPIDEM

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

Prior authorization is required for patients 65 years and older. Prior authorization is not required for patients 64 years and younger.

**Prescriber Restrictions:**

**Coverage Duration:**

12 months.

**Other Criteria:**

Failure of two of the following, unless contraindicated or clinically significant adverse effects are experienced:  
Rozerem, Silenor 6 mg/day or less, trazodone or temazepam.

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

**Prior Authorization Group Description:**

ZYDELIG

**Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with a hematologist or oncologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

## **Prior Authorization Protocol**

---

### **Medicare Part D – 2019**

#### **Prior Authorization Group Description:**

ZYKADIA

#### **Covered Uses:**

All medically accepted indications not otherwise excluded from Part D.

#### **Exclusion Criteria:**

#### **Required Medical Information:**

NON-SMALL Cell LUNG CANCER: Documentation of ALK or ROS1 positive disease. INFLAMMATORY MYOFIBROBLASTIC TUMOR: Documentation of ALK-positive disease.

#### **Age Restrictions:**

#### **Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist.

#### **Coverage Duration:**

12 months.

#### **Other Criteria:**



## Prior Authorization Protocol

---

### Medicare Part D – 2019

**Prior Authorization Group Description:**

ZYTIGA

**Covered Uses:**

All FDA-approved indications not otherwise excluded from Part D.

**Exclusion Criteria:**

**Required Medical Information:**

**Age Restrictions:**

**Prescriber Restrictions:**

Prescribed by or in consultation with an oncologist or urologist.

**Coverage Duration:**

12 months.

**Other Criteria:**

Prescribed in combination with prednisone. Member has previously had bilateral orchiectomy, failed androgen deprivation therapy (ADT) or will use ADT concurrently with Zytiga.

ABSTRAL.....	1	CLADRIBINE.....	48
ACTEMRA SC.....	2	CLOMIPRAMINE.....	49
ACTIQ.....	3	COMETRIQ.....	50
ACYCLOVIR.....	4	COPIKTRA.....	51
ADCIRCA.....	5	COTELLIC.....	52
ADEMPAS.....	6	CRINONE.....	53
AFINITOR.....	7	CROFELEMER.....	54
AIMOVIG.....	8	CRYSVITA.....	55
AJOVY.....	9	CYCLOBENZAPRINE HCL.....	56
ALECENSA.....	10	CYTARABINE.....	57
ALUNBRIG.....	11	DAKLINZA.....	58
AMITRIPTYLINE.....	12	DAURISMO.....	59
AMITRIPTYLINE/CHLORDIAZEPOXIDE.....	13	DIPYRIDAMOLE.....	60
AMITRIPTYLINE/PERPHENAZINE.....	14	DISOPYRAMIDE.....	61
AMPHOTERICIN B.....	15	DOPTELET.....	62
AMPYRA.....	16	DOXEPIN.....	63
ANTI-HISTAMINES.....	17	ELIDEL.....	64
ANTI-HISTAMINE COMBINATIONS.....	18	EMEND 40 MG.....	65
ARANESP.....	19	EMFLAZA.....	66
ARIKAYCE.....	20	EMGALITY.....	67
AUBAGIO.....	21	ENBREL.....	68
AUSTEDO.....	22	ENDARI.....	69
AVASTIN.....	23	ENTRESTO.....	70
BALVERSA.....	24	ENTYVIO.....	71
BAXDELA.....	25	EPCLUSA.....	72
BELEODAQ.....	26	EPIDIOLEX.....	73
BELSOMRA.....	27	EPOETIN.....	74
BENLYSTA.....	28	ERGOLOID MESYLATES.....	75
BENZTROPINE.....	29	ERLEADA.....	76
BLEOMYCIN.....	30	ESBRIET.....	77
BOSULIF.....	31	ESTROGENS(Fyavolv , Mimvey Lo , Minivelle , Femhrt , Vivelle-Dot , Menostar , Premphase , Premarin , Lopreeza , Alora , Amabelz , Prempro , Mimvey , Climara Pro , Combipatch , Angeliq , Elestrin , Climara , Divigel , Duavee , Activella , Estrace , Evamist , estropipate).....	78
BOTOX.....	32	EVZIO.....	79
BRAFTOVI.....	33	EXONDYS 51.....	80
BRIVIACT.....	34	EYLEA.....	81
BUTABARBITAL.....	35	FARYDAK.....	82
C1 ESTERASE INHIBITOR.....	36	FASENRA.....	83
CABOMETYX.....	37	FENTORA.....	84
CALQUENCE.....	38	FERRIPROX.....	85
CAPRELSA.....	39	FIORICET WITH CODEINE.....	86
CARISOPRODOL/ASPIRIN.....	40	FIORINAL WITH CODEINE.....	87
CARISOPRODOL/ASPIRIN/CODEINE.....	41	FIRAZYR.....	88
CAYSTON.....	42	FIRDAPSE.....	89
CERDELGA.....	43	FLECTOR.....	90
CEREZYME.....	44	FLUOROURACIL.....	91
CHLORZOXAZONE.....	45		
CHORIONIC GONADOTROPIN.....	46		
CINQAIR.....	47		

FORTEO.....	92	KEVZARA.....	139
GALAFOLD.....	93	KEYTRUDA.....	140
GANCICLOVIR.....	94	KISQALI(Kisqali , Kisqali Femara Co-Pack ).....	141
GATTEX.....	95	KORLYM.....	142
GILENYA.....	96	KUVAN.....	143
GILOTRIF.....	97	KYNAMRO.....	144
GLATIRAMER.....	98	LATUDA.....	145
GLYBURIDE.....	99	LAZANDA.....	146
GLYBURIDE/METFORMIN.....	100	LEMTRADA.....	147
GOCOVRI.....	101	LENVIMA.....	148
GRANIX.....	102	LEUKINE.....	149
GRASTEK.....	103	LIDODERM.....	150
HARVONI.....	104	LONSURF.....	151
HERCEPTIN.....	105	LORBRENA.....	152
HETLIOZ.....	106	LOTRONEX.....	153
HUMAN GROWTH HORMONE.....	107	LUCEMYRA.....	154
HUMIRA.....	108	LUNESTA.....	155
HYDROCODONE.....	109	LYNPARZA CAPSULE.....	156
HYDROXYZINE HCL.....	110	LYNPARZA TABLET.....	157
HYDROXYZINE HCL INJECTION.....	111	MAVYRET.....	158
HYDROXYZINE PAMOATE.....	112	MEGACE.....	159
ICLUSIG.....	113	MEGACE ES.....	160
IDHIFA.....	114	MEKINIST.....	161
ILARIS.....	115	MEKTOVI.....	162
ILUMYA.....	116	MEPERIDINE.....	163
IMATINIB.....	117	MEPROBAMATE.....	164
IMBRUVICA.....	118	METAXALONE.....	165
IMIPRAMINE.....	119	METHAMPHETAMINE.....	166
INDOMETHACIN.....	120	METHOCARBAMOL.....	167
INFLECTRA.....	121	METHOTREXATE INJ.....	168
INGREZZA.....	122	METHYLDOPA.....	169
INLYTA.....	123	MIRVASO.....	170
INTERFERON BETA-1A.....	124	MOZOBIL.....	171
INTERFERON BETA-1B.....	125	MULPLETA.....	172
INTERMEZZO 1.75 MG.....	126	NAMENDA.....	173
INTERMEZZO 3.5 MG.....	127	NATPARA.....	174
INTUNIV.....	128	NERLYNX.....	175
JAKAFI.....	129	NEULASTA.....	176
JUBLIA.....	130	NEUPOGEN.....	177
JUXTAPID.....	131	NINLARO.....	178
JYNARQUE.....	132	NITROFURANTOIN.....	179
KADCYLA.....	133	NIVESTYM.....	180
KADIAN.....	134	NORTHERA.....	181
KALYDECO.....	135	NUCALA.....	182
KERYDIN.....	136	NUEDEXTA.....	183
KETOROLAC TROMETHAMINE.....	137	NUPLAZID.....	184
KEVEYIS.....	138	NUVIGIL.....	185

NUZYRA.....	186	SOMAVERT.....	233
OCALIVA.....	187	SONATA.....	234
OCREVUS.....	188	SOVALDI.....	235
ODOMZO.....	189	SPRAVATO.....	236
OFEV.....	190	SPRITAM.....	237
OLUMIANT.....	191	SPRYCEL.....	238
OPSUMIT.....	192	STIVARGA.....	239
ORALAIR.....	193	STRENSIQ.....	240
ORENITRAM.....	194	SUBSYS.....	241
ORILISSA.....	195	SURMONTIL.....	242
ORKAMBI.....	196	SYMDEKO.....	243
ORPHENADRINE.....	197	SYMLINPEN.....	244
OSMOLEX ER.....	198	SYMPAZAN.....	245
OXERVATE.....	199	TAGRISSE.....	246
PALYNZIQ.....	200	TAKHZYRO.....	247
PENTAZOCINE/NALOXONE.....	201	TALZENNA.....	248
PERSERIS.....	202	TARCEVA.....	249
PHENOBARBITAL.....	203	TASIGNA.....	250
PRALUENT.....	204	TAVALISSE.....	251
PREVYMIS.....	205	TECENTRIQ.....	252
PROCARDIA CAPSULES.....	206	TECFIDERA.....	253
PROLASTIN C.....	207	TEGSEDI.....	254
PROLIA.....	208	TENEX.....	255
PROMACTA.....	209	TETRABENAZINE.....	256
PROTOPIC.....	210	TIBSOVO.....	257
PROVIGIL.....	211	TREMFYA.....	258
PURIXAN.....	212	TRIHEXYPHENIDYL.....	259
QUALAQUIN.....	213	TYMLOS.....	260
RADICAVA.....	214	TYSABRI.....	261
RAYALDEE.....	215	ULTRAVATE LOTION.....	262
RELISTOR.....	216	UPTRAVI.....	263
REMICADE.....	217	VALCHLOR.....	264
REPATHA.....	218	VANCOCIN.....	265
RESTASIS.....	219	VENCLEXTA.....	266
REVATIO.....	220	VERSACLOZ.....	267
REVCovi.....	221	VERZENIO.....	268
REVLIMID.....	222	VIBERZI.....	269
REXULTI.....	223	VIMOVO.....	270
RITUXIMAB.....	224	VINBLASTINE.....	271
RUBRACA.....	225	VINCRISTINE.....	272
RYDAPT.....	226	VITRAKVI.....	273
SAVELLA.....	227	VIZIMPRO.....	274
SEROQUEL XR.....	228	VOSEVI.....	275
SILIQ.....	229	VOTRIENT.....	276
SIMPONI(auto-injector, prefilled syringe).....	230	VRAYLAR.....	277
SIMPONI ARIA.....	231	XALKORI.....	278
SOMA.....	232	XATMEP.....	279

XELJANZ.....	280
XEOMIN.....	281
XERMELO.....	282
XOLAIR.....	283
XOSPATA.....	284
XTANDI.....	285
YERVOY.....	286
YONSA.....	287
ZALTRAP.....	288
ZARXIO.....	289
ZEJULA.....	290
ZELBORAF.....	291
ZEPATIER.....	292
ZINPLAVA.....	293
ZOLPIDEM.....	294
ZYDELIG.....	295
ZYKADIA.....	296
ZYTIGA.....	297